SCYNEXIS (SCYX), Tuesday reported positive Phase 1 results for its next-generation triterpenoid antifungal for invasive fungal infections, SCY-247. SCY-247 was well tolerated, with only mild to moderate adverse events reported in the study, which involved 88 healthy participants.
Compared to the company's first-generation medication, oral doses produced target exposures at lower levels, indicating better tolerability.
Further development was supported by SCY-247's dose-proportional pharmacokinetics and effective exposures against resistant Candida strains in models.
SCYX is currently trading at $0.75, down $0.29 or 28.56 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.